Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation

Table 1 Flow cytometry analysis of the positive cells treated with LaDR5 (10 μg/mL) in different tumor cell lines

LaDR5 could bind the membrane DR5 on Jurkat (the percentage of positive cells was 57.05 %), Daudi (63.78 %) and U937 (86.07 %), which was essentially consistent with the standard anti-DR5 antibody treated samples (79.12 % in Jurkat, 95.45 % in Daudi and 98.18 % in U937). In K562 cells, the percentage of positive cells in standard anti-DR5 antibody treated sample was 10.92 % contrasting to 0.4 % in LaDR5 incubated sample.

ISSN: 1471-2172